Jardiance (Empagliflozin) and Eplerenone: Approved Indications
Jardiance (empagliflozin) is prescribed for type 2 diabetes mellitus, heart failure (both reduced and preserved ejection fraction), and chronic kidney disease, while eplerenone is prescribed for heart failure with nonreduced ejection fraction (LVEF >40%). These medications address distinct but sometimes overlapping cardiovascular and metabolic conditions.
Jardiance (Empagliflozin) Indications
Type 2 Diabetes Mellitus
Empagliflozin is FDA-approved to improve glycemic control in adults and children aged 10-17 years with type 2 diabetes as an adjunct to diet and exercise 1. The drug works by inhibiting renal glucose reabsorption, producing glucosuria and reducing HbA1c by approximately 0.7-0.9% compared to placebo 1.
Heart Failure - All Ejection Fractions
Empagliflozin is indicated for symptomatic chronic heart failure regardless of ejection fraction 2. This represents a major therapeutic advance:
Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF ≤40%): The EMPEROR-Reduced trial demonstrated a 25% reduction in cardiovascular death or heart failure hospitalization 3, 4. Benefits emerged within 12 days of treatment initiation and persisted throughout follow-up 4.
Heart Failure with Preserved Ejection Fraction (HFpEF, LVEF >40%): The EMPEROR-Preserved trial showed a 21% reduction in the composite endpoint of cardiovascular death or heart failure hospitalization 5, 6. The benefit was consistent regardless of diabetes status 2.
Acute Decompensated Heart Failure: The EMPULSE trial demonstrated that initiating empagliflozin during hospitalization for acute heart failure (median 3 days after admission) improved clinical outcomes at 90 days with a win ratio of 1.36 7.
The 2025 Canadian guidelines strongly recommend SGLT2 inhibitors like empagliflozin as first-tier therapy for heart failure with nonreduced ejection fraction, with starting doses of 10 mg daily and target doses of 10-25 mg daily 2.
Chronic Kidney Disease
The EMPA-KIDNEY trial established empagliflozin's role in chronic kidney disease 8. Empagliflozin reduces kidney disease progression and cardiovascular death in patients with eGFR ≥20 mL/min/1.73 m² and albuminuria 9, 8. The trial showed a 28% reduction in the composite of kidney disease progression or cardiovascular death, with benefits consistent regardless of diabetes status 8.
Cardiovascular Risk Reduction in Type 2 Diabetes
The EMPA-REG OUTCOME trial demonstrated that empagliflozin reduces cardiovascular death by 38%, heart failure hospitalization by 35%, and all-cause mortality by 32% in patients with type 2 diabetes and established cardiovascular disease 10, 11. This led to FDA approval for reducing cardiovascular death risk in this population 12.
Eplerenone Indications
Heart Failure with Nonreduced Ejection Fraction
Eplerenone is a mineralocorticoid receptor antagonist (MRA) indicated for heart failure with LVEF >40% 2. The 2025 Canadian guidelines list eplerenone as an evidence-based medication for HFnrEF with:
- Starting dose: 25 mg daily
- Target dose: 50 mg daily 2
Eplerenone works by blocking aldosterone receptors, reducing sodium retention, myocardial fibrosis, and vascular inflammation. It is positioned as a treatment option alongside SGLT2 inhibitors, ARNIs, and ARBs for managing heart failure with preserved or mildly reduced ejection fraction 2.
Key Monitoring Considerations
For eplerenone, monitor serum potassium and renal function closely, as hyperkalemia is the primary safety concern. The FIDELIO-DKD trial with the related MRA finerenone showed 2.3% discontinuation due to hyperkalemia versus 0.9% with placebo, though no deaths occurred 9.
Clinical Pearls
Empagliflozin benefits extend beyond glucose lowering: Effects on heart failure and kidney disease occur independently of diabetes status 10, 2, 3.
Early initiation matters: For heart failure, empagliflozin shows benefits within days to weeks of starting treatment 4.
Dosing in renal impairment: Empagliflozin can be initiated with eGFR ≥20 mL/min/1.73 m² for kidney and heart failure indications, though glucose-lowering efficacy diminishes below eGFR 45 mL/min/1.73 m² 1, 8.
Safety profile: Empagliflozin is generally well-tolerated with low rates of hypoglycemia, volume depletion, and ketoacidosis when used appropriately 10, 3. Genital infections occur more frequently but are typically mild 11.